Table 4. Evaluation of coagulation function in the aspirin, rt-PA, rPA, rt-PA + aspirin, and rPA + aspirin groups.
| Coagulation function | Time | Aspirin group (n = 117) | rt-PA group (n = 121) | rPA group (n = 123) | rt-PA + aspirin group (n = 126) | rPA + aspirin group (n = 124) |
|---|---|---|---|---|---|---|
| PT (t/s) | Before treatment | 11.7 ± 3.6 | 11.98 ± 3.54 | 11.8 ± 3.72 | 11.9 ± 3.9 | 12.0 ± 3.7 |
| 30 days after treatment | 13.45 ± 3.211 | 13.34 ± 3.521 | 13.40 ± 3.381 | 15.4 ± 3.671,2 | 15.6 ± 3.701,2 | |
| APTT (t/s) | Before treatment | 29.32 ± 3.42 | 30.07 ± 3.35 | 29.3 ± 3.45 | 29.34 ± 3.6 | 29.41 ± 3.32 |
| 30 days after treatment | 36.41 ± 2.51 | 37.51 ± 2.121 | 37.55 ± 2.811 | 39.8 ± 2.81,2 | 39.9 ± 3.61,2 | |
| FIB (p/g·L-1) | Before treatment | 3.78 ± 1.64 | 3.80 ± 1.52 | 3.77 ± 1.57 | 3.76 ± 1.62 | 3.81 ± 1.59 |
| 30 days after treatment | 1.95 ± 0.51 | 1.93 ± 0.691 | 1.98 ± 0.691 | 1.54 ± 0.771,2 | 1.54 ± 0.741,2 |
Notes: rPA, Reteplase; rt-PA, Alteplase.1P < 0.05, compared with the same group before treatment. 2P < 0.05, compared with the aspirin, rt-PA, rPA groups at the same time.